- Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
- Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
- Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
- Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
- Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19
- Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
- U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
- European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
- European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
- FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
More ▼
Key statistics
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 246.00 |
Average volume | -- |
---|---|
Shares outstanding | 809.25m |
Free float | 728.90m |
P/E (TTM) | 19.92 |
Market cap | 267.02bn CHF |
EPS (TTM) | 16.19 CHF |
Annual div (ADY) | 8.95 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 17 2022 |
Div pay-date | Mar 21 2022 |
Data delayed at least 15 minutes, as of Jun 28 2019 17:58 BST.
More ▼